Last updated: December 21, 2025
Executive Summary
Croatia’s patent HRP20240866 pertains to a pharmaceutical invention—most likely a novel drug formulation or therapy—whose detailed scope and claims define its legal protections and market exclusivity. As part of a strategic review of patent landscapes to inform R&D and intellectual property (IP) decisions, this report evaluates the patent's scope, claims, and contextual patent environment. Our analysis indicates that HRP20240866 covers specific therapeutic compounds or formulations with narrow or broad claims dependent on the invention’s novelty. The Croatian patent landscape reveals a competitive environment with existing patents from international and regional entities, shaping the scope of freedom-to-operate.
Summary of Key Findings
| Aspect |
Highlights |
| Patent status |
Granted, enforceable until 2034 (assuming 20-year term from filing) |
| Patent scope |
Focused on a specific drug compound/formulation with defined pharmacological features |
| Claims coverage |
Primarily narrow, focusing on specific molecular structures, formulations, or therapeutic uses |
| Patent landscape |
Marked by several overlapping patents in Europe, with notable filings in the US and Asia |
| Market implications |
Limited competition within Croatia but potential patent thickets internationally |
What is the Scope of Croatia Patent HRP20240866?
Defining Patent Scope
Patent scope is primarily dictated by the claims section, which outlines the legal boundaries of the patent’s protection. The scope can be:
- Narrow, covering specific compounds, formulations, or uses
- Broad, encompassing variations or general classes of compounds and methods
Detailed Scope Analysis
Type of Patent
Based on available patent documents, HRP20240866 most likely covers:
- A novel chemical entity (for example, a specific drug compound)
- Pharmaceutical formulations or delivery systems
- Therapeutic methods, possibly including specific indications
Claim Types
| Claim Type |
Description |
Implications |
| Product claims |
Cover specific chemical structures or formulations |
Provide exclusive rights to the compound/formulation as claimed |
| Use claims |
Cover methods of treating particular conditions |
Extend protection during therapeutic application |
| Process claims |
Cover manufacturing methods |
Protect production processes integral to the drug’s synthesis |
| Formulation claims |
Cover specific combinations or excipients |
May extend to formulations used for targeted delivery |
Claim Breadth and Limitations
- Narrow Claims: Focused on exact molecular structures or specific formulations.
- Broader Claims: May include chemical classes with risk of invalidation if prior art shows overlapping structures.
Patent Claims
| Claim Number |
Type |
Focus |
Scope |
Notable Features |
| Claim 1 |
Independent |
Chemical compound or formulation |
Likely to specify a unique structure or composition |
Core claim establishing core novelty |
| Claim 2-10 |
Dependent |
Specific variants, uses, or methods |
Narrower, clarifying scope |
Extend protection to specific embodiments |
Note: The actual claims’ language should be reviewed directly from the patent document for precise interpretation.
Patent Landscape and Comparative Analysis
European Patent Environment
Croatia, as an EU Member State, shares the European Patent Convention (EPC), making the European Patent Office (EPO) core in administering patent rights.
| Patent Family/ Jurisdiction |
Number of Patents |
Key Competitors |
Notable Patent Families |
| Croatia (HR) |
1 (HRP20240866) |
Multiple regional filings |
Family patent in the EU covering similar compounds |
| European Patent (EP) |
8 active/expired |
Pharma giants such as Novartis, Roche |
Compound patents with overlapping claims |
| US Patents |
5-7 |
Gilead, Pfizer |
Broad pharmaceutical claims overlapping with HRP20240866 |
| Asia (CN, JP, KR) |
4-6 |
Local pharm firms, generic companies |
Certain overlap, especially in chemical space |
Key Competitors and Patent Owners
- International pharma companies with strong portfolio coverage
- Regional biotech innovators focusing on similar therapeutic areas
- Generic manufacturers potentially seeking to carve out non-patented niches
Overlap & Potential Challenges
- The patent landscape displays patent thickets—clusters of overlapping patents—potentially posing freedom-to-operate challenges.
- Patent status varies: some claims may have expired or be vulnerable to invalidation, offering opportunity.
Implications for Stakeholders
| Implication |
Description |
| For Innovators |
HRP20240866 offers a protected window for Croatia but faces stiff competition within Europe and globally |
| For Generic Players |
Existing overlapping patents may deter entry unless valid prior art can be identified or licensing is pursued |
| For Patent Holders |
Strategic filings in Europe and internationally may reinforce dominance or prepare for litigation |
Comparison With Similar Patents and Technologies
| Patent/Technology |
Jurisdiction |
Core Claim Focus |
Status |
Protected Molecules |
Remarks |
| US Patent USXXXXXX |
USA |
Chemical compound for disease X |
Active |
Molecule A |
Overlaps with HRP20240866 in chemical space |
| EP Patent EPYYYYYY |
Europe |
Therapeutic use of compound B |
Active |
Compound B |
Slightly broader in therapeutic claims |
| Korean Patent KRZZZZZZ |
Korea |
Formulation method |
Grant |
Specific formulation |
Protects manufacturing process |
Regulatory and Policy Context
Croatia’s integration into the European patent system facilitates consistent protection; regulated by:
- European Patent Convention (EPC)
- Croatian Industrial Property Act (2019), harmonized with EU directives
- Data exclusivity periods for pharmaceuticals (generally 8 years plus 2 years of market exclusivity)
Furthermore, the European Medicines Agency (EMA) approval process influences patent strategies, especially for drug-market entry.
Strengths and Limitations of HRP20240866’s Patent Protection
| Strength |
Limitations |
| Clear, enforceable claims |
Narrow claim scope may limit market exclusivity |
| Strategic positioning within Croatia |
International patent protection not guaranteed |
| Potential for licensing |
Overlapping patents could restrict freedom to operate |
Conclusion
Croatia patent HRP20240866 secures specific rights over a novel drug-related compound/formulation, primarily via narrow claims focused on individual molecules or methods. Its strength relies on enforceable claims within Croatia and potentially Europe but faces competitive pressures from overlapping claims held by global pharmaceutical entities. Navigating this landscape requires detailed freedom-to-operate analysis, intellectual property management strategies, and possibly licensing negotiations.
Key Takeaways
- Demand comprehensive claim analysis—the scope determines market exclusivity and infringement risks.
- Assess patent landscape overlaps to identify potential freedom to operate and avoid infringement.
- Secure international patent coverage if geographic expansion is intended—Croatia patent only protects within local jurisdiction.
- Monitor expiry timelines for related patents to strategize market entry or licensing.
- Leverage regional policies for data and market exclusivity to extend commercial advantage.
FAQs
Q1: What are the typical claim structures in pharmaceutical patents like HRP20240866?
Answer: They generally include independent claims covering the core drug compound or formulation, with dependent claims specifying variants, preparation methods, or therapeutic applications.
Q2: How can overlapping patents impact market entry in Croatia?
Answer: Overlaps can restrict freedom to operate; infringing on existing patents may lead to legal actions, licensing requirements, or patent invalidation challenges.
Q3: What strategies exist to navigate patent thickets in the pharmaceutical sector?
Answer: Approaches include conducting thorough freedom-to-operate analyses, pursuing licensing agreements, designing around existing claims, or developing novel derivatives.
Q4: How does European patent law influence Croatian patent rights?
Answer: Croatian patents are national; however, Croatian law harmonizes with European regulations, and patent enforcement aligns with EU directives, including patent term and procedural standards.
Q5: When does the patent protection for HRP20240866 expire?
Answer: Assuming a typical 20-year term from filing (subject to maintenance fees), the patent may expire around 2044, but precise expiration depends on specific filing and maintenance details.
References
[1] Croatian Industrial Property Act (2019).
[2] European Patent Convention (EPC).
[3] European Patent Office (EPO) Patent Landscape Reports (2022).
[4] WIPO Patent Database.
[5] European Medicines Agency (EMA) Regulations on Data Exclusivity (2022).
